· Published by Health Canada · Official notice
This is duplicated text of a letter from the Hospira Healthcare Corporation. Contact the company for a copy of any references, attachments or enclosures.
October 29, 2012
Dear Healthcare Professional,
Please distribute to relevant Departments (Oncology, Pharmacy, Geriatrics, Internal Medicine, Nursing, and/or other Departments as required), and other involved professional staff and post this NOTICE in your institution.
Subject: Visible particles in one lot of Carboplatin injection, 600mg/60mL (DIN 02126680)
Hospira Healthcare Corporation, in consultation with Health Canada, would like to inform you that a recall has been initiated of one lot of Carboplatin injection (identified below) distributed in Canada due to visible crystal like particulate matter observed during an inspection of retained samples. The lot was distributed in Canada between March 2012 and June 2012.
Carboplatin is a platinum coordination compound that is used as a cancer chemotherapeutic agent. Carboplatin Injection is indicated in the treatment of ovarian cancer of epithelial origin in first line therapy, and in second line therapy after other treatments have failed.
Affected lot of Carboplatin subject to recall from the Canadian market:
Z011710AB: Expiry date: August 2013
Injected particulate matter may result in acute local inflammation, phlebitis and/or generalized low-level allergic reaction and /or embolization to other organs in the body. Hospira has not received reports of any adverse events associated with this issue for this lot.
Replacement lots of carboplatin are available and no market shortage is expected in Canada as a result of this recall.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-market adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any cases of serious adverse reaction or other serious or unexpected adverse reactions in patients receiving Carboplatin Injection (600mg/60mL) should be reported to Hospira Healthcare Corporation or Health Canada at the following addresses:
Hospira Healthcare Corporation
Complaint & Safety Department
1111 Dr.-Frederik-Philips, Suite 600
Saint-Laurent (Québec) H4M 2X6
To report an Adverse Reaction, consumers and health professionals may call toll free :
Tel: 1-866-488-6088 Option 6
Fax: 1-877-906-0208
ProductcomplaintsCA@hospira.com
To correct your mailing address or fax number, contact the Hospira Healthcare Corporation.
To report suspected adverse reactions to these or other health products, please contact Health Canada's Canada Vigilance Program toll-free at 1-866-234-2345, or visit the MedEffect™ Canada Web site for information on how to report.
The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffect™ Canada Web site in the Adverse Reaction Reporting section. The Reporting Form is also in the Canadian Compendium of Pharmaceuticals and Specialties.
For other health product inquiries related to this communication, please contact Health Canada at:
Health and Product and Food Branch Inspectorate
E-mail: DCVIU_UVECM@hc-sc.gc.ca
Telephone: 1-800-267-9675
Fax: 1-613-946-5636
Sincerely,
original signed by
Rania Al-Ammar
Regional Director, Commercial Quality
Hospira Healthcare Corporation